With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen

FDA approval of Crinetics Pharmaceuticals’ Palsonify makes it the first oral first-line therapy for acromegaly, a rare endocrine disorder. The once-daily pill will compete with blockbuster acromegaly drugs from Novartis and Ipsen that are administered as injections. The post With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen appeared…

Read More

4 Execs’ Wishes for a Better Healthcare Future

At DiMe’s Healthcare 2030 Summit, four healthcare leaders shared the innovations they believe could most improve care, from AI-driven solutions to reduce medical errors to stronger primary care relationships that could save billions. The post 4 Execs’ Wishes for a Better Healthcare Future appeared first on MedCity News.

Read More

4 Execs’ Wishes for a Better Healthcare Future

At DiMe’s Healthcare 2030 Summit, four healthcare leaders shared the innovations they believe could most improve care, from AI-driven solutions to reduce medical errors to stronger primary care relationships that could save billions. The post 4 Execs’ Wishes for a Better Healthcare Future appeared first on MedCity News.

Read More